Eli Lily to Acquire Disarm Therapeutics for ~$1.36B

Shots: Lilly to acquire Disarm for $135M upfront and ~$1.225B as potential development regulatory and commercial milestones, making a total deal value of ~1.36B The acquisition will expand Lilly’s R&D efforts in pain and neurodegeneration with the addition of Disarm’s preclinical SARM1 programs for axonal degeneration Disarm is advancing its potent SARM1 inhibitors in preclinical …

Eli Lily to Acquire Disarm Therapeutics for ~$1.36B Read More »